Volume 68 Numbers 4 & 5 September / October 2001	back to contents

Current Therapy of Pemphigus Vulgaris	268–278
Michael J. Fellner, M.D., and Allen N. Sapadin, M.D.
Address correspondence to Michael J. Fellner, M.D., Department of Dermatology, Box 1047, Mount Sinai School of Medicine, One East 100th Street, New York, NY 10029.

ABSTRACT
Pemphigus vulgaris (PV) is a potentially fatal autoimmune blistering disease of the skin and mucous membranes, characterized by flaccid bullae that rupture and leave erosions. Its treatment is challenging. Although the use of systemic corticosteroids remains the cornerstone of effective therapeutic regimens for PV, their prolonged administration may lead to serious side effects. It is therefore necessary, for many patients, to add immunosuppressive agents or use immunomodulatory procedures to achieve remission. This paper will summarize the treatments available for PV, while focusing on the most recently available therapeutic options.

KEY WORDS
Pemphigus vulgaris, therapy

MSSM Home

Back Issues | Indexes | Search | Journal Home